CAS: 232275-51-3; 4-Bromo-2,6-Dichlorobenzoic Acid

上下游产品

2,6-二氯-4-溴苯甲酸甲酯 Methyl 4-Bromo-2,6-Dichlorobenzoate 232275-53-5
2,6-二氯苯甲酸 2,6-Di-Chlorobenzoic Acid 50-30-6
3-氨基-4-溴-2,6-二氯苯甲酸 3-Amino-4-Bromo-2,6-Dichlorobenzoic Acid 1415124-69-4
4-氨基-2,6-二氯苯甲酸甲酯 Methyl 4-Amino-2,6-Dichlorobenzoate 232275-49-9
3-氨基-2,6-二氯苯甲酸 5-Amino-2,6-Dichloro-Benzoic Acid 50917-29-8

2,6-二氯苯甲酸置于盐酸,N-溴代丁二酰亚胺(Nbs),硫酸,硝酸,四氯化锡,Sodium Nitrite体系中,化学反应 4.75H,反应生成2,6-二氯-4-溴苯甲酸
参考文献:Heterocyclic Compounds As Protein Kinase Inhibitors
标题:Heterocyclic Compounds As Protein Kinase Inhibitors
摘要:本发明提供了一种异环化合物,其化学式为(i),其药学上可接受的盐,其前药或水合物,其中a,A',B,D,R1,R2和r3如本文所定义,包括一种以化合物(i)为活性成分的药物组合物,生产方法以及使用方法.特别是,本发明提供了一种化合物(i),用于治疗或预防与蛋白激酶相关的疾病,症状或紊乱,优选为janus激酶家族.

专利信息

专利号:US-2022363662-A1
优先权日:2021-04-20
标题 :Compounds as lxr agonists
发明人：PUJALA BRAHMAM; SATHE BALAJI DASHRATH; DANODIA ABHINANDAN; GUPTA ASHU; SONI SANJEEV; KUMAR VIVEK; ANSARI AMANTULLAH; KHAN FARHA; SARKAR ARINDAM; PAYGHAN PAVAN V
权利人:INTEGRAL BIOSCIENCES PRIVATED LTD
摘要:The present invention generally discloses compounds having LXR (the liver X receptor) agonistic activity, to the use of such compounds in the treatment of various disorders such as proliferative disorders, Alzheimer's disease, inflammatory diseases, and diseases characterized by defects in cholesterol and lipid metabolism. Specifically, the present invention discloses compound of formula (IA) which exhibit LXR agonist activity, specifically to LXRβ. The invention also discloses method of synthesis of said compounds, method of using said compounds, pharmaceutical compositions comprising said compounds and method of using thereof.